Table 4 Description of injectable regimens, toxicities and discontinuation among participants on MDR-TB treatment follow-up at St.Peter’s Specialized Hospital and ALERT center, Addis Ababa, Ethiopia
Characteristics | N(%) |
|---|---|
Type of injectable drug used | |
 Capreomycin | 789 (84.7) |
 Kanamycin | 37 (5.6) |
 Amikacin | 40 (4.3) |
 Streptomycin | 2 (0.2) |
Mean (± SD) duration on injectable treatment (months) | 8.51 ± 2.3 |
Mean (± SD) total dose of injectables received(g) | 158.5 ± 56.2 |
Switching of injectable | 49 (5.3) |
Discontinuation of injectable due to toxicity | 34 (3.9) |
 Hearing disturbance/ototoxicity | 8 (0.9) |
 Nephrotoxicity/clinical renal failure | 26 (2.9) |
Clinically diagnosed nephrotoxicity | 62 (6.7) |
Clinically diagnosed ototoxicity | 42 (4.8) |
 Hearing loss | 16 (1.8) |
 Imbalance | 7 (0.8) |
 Visual disturbance | 19 (2.2) |